Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In metabolic syndrome, blood levels of apolipoprotein B (Apo B) reveal the presence of quantitative and qualitative alterations of atherogenic lipoproteins and therefore represent an indicator of the risk of developing cardiovascular disease (CVD). The objective of this study is to evaluate the effect of a combined dietary supplement containing glucomannan, white mulberry dry extract (d.e.), gymnema (d.e.), olive (d.e.), Cassia nomame (d.e.), Nopal, policosanols and chromium, compared to placebo, on Apo B in individuals with metabolic syndrome adhering to the Mediterranean diet. Furthermore, the effect of the dietary supplement on anthropometric parameters, waist circumference and body composition will be investigated.
Metabolic syndrome is a highly prevalent condition characterized by the simultaneous presence of multiple cardiometabolic risk factors, such as arterial hypertension, atherogenic dyslipidemia, hyperglycemia and abdominal obesity. According to the International Atherosclerosis Society (IAS), metabolic syndrome is a clustering of at least three of the following five medical conditions:
Troubling increases in high FPG, high body mass index (BMI), and other risk factors related to obesity and metabolic syndrome indicate an urgent need to identify and implement interventions, as shown by the Global Burden of Disease (GBD) Study Group. To date, several active ingredients of natural origin have been shown to favorably modify the individual components that have revealed the presence of metabolic syndrome. Among these, we find glucomannan and white mulberry dry extract.
The purpose of this study is to evaluate if a dietary supplement containing glucomannan, white mulberry dry extract (d.e.), gymnema (d.e.), olive (d.e.), Cassia nomame (d.e.), Nopal, policosanols and chromium, is able to significantly influence serum levels of apo B in individuals with metabolic syndrome adhering to the Mediterranean diet. Furthermore, the effect of the dietary supplement on anthropometric parameters, waist circumference and body composition will be investigated.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Food Supplement | Active Comparator | The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium. |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Food Supplement | Dietary Supplement | The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of the Dietary Supplement on Apo B | The primary objective is to compare the effect on Apo B after 12 weeks of treatment with the dietary supplement or placebo, in combination with the Mediterranean diet (Standard of Care - SOC). | From enrollment to the end of treatment at 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of the Dietary Supplement on changes in body water | To evaluate the effect of the dietary supplement on changes in body water compared baseline and placebo after 12 weeks of treatment. | From enrollment to the end of treatment at 12 weeks |
| Effect of the Dietary Supplement on changes in lean body mass |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Arrigo Francesco Giuseppe Cicero, MD, PhD | Contact | +39 051 214290 | arrigo.cicero@unibo.it |
| Name | Affiliation | Role |
|---|---|---|
| Arrigo Francesco Giuseppe Cicero, MD, PhD | University of Bologna | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IRCCS AOU di Bologna | Bologna | Bologna | 40100 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| ID | Term |
|---|---|
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Other | Placebo |
|
To evaluate the effect of the dietary supplement on changes in lean body mass compared baseline and placebo after 12 weeks of treatment. |
| From enrollment to the end of treatment at 12 weeks |
| Effect of the Dietary Supplement on changes in fat body mass | To evaluate the effect of the dietary supplement on changes in fat body mass compared baseline and placebo after 12 weeks of treatment. | From enrollment to the end of treatment at 12 weeks |
| Effect of the Dietary Supplement on changes in waist circumference | To evaluate the effect of the dietary supplement on changes in waist circumference compared baseline and placebo after 12 weeks of treatment. | From enrollment to the end of treatment at 12 weeks |
| Dietary Supplement use and prevalence of Metabolic Syndrome | To verify whether the intake of the dietary supplement is associated with a reduction in the prevalence of metabolic syndrome, compared to baseline and compared to placebo, after 12 weeks of treatment. | From enrollment to the end of treatment at 12 weeks |
| Effect of the Dietary Supplement on changes in body water midway through the study | To evaluate the effect of the dietary supplement on changes in body water compared baseline and placebo after 6 weeks of treatment | From enrollment to 6-week follow-up |
| Effect of the Dietary Supplement on changes in lean body mass midway through the study | To evaluate the effect of the dietary supplement on changes in lean body mass compared baseline and placebo after 6 weeks of treatment. | From enrollment to 6-week follow-up |
| Effect of the Dietary Supplement on changes in fat body mass effect on cholesterol midway through the study | To evaluate the effect of the dietary supplement on changes in fat body mass compared baseline and placebo after 6 weeks of treatment. | From enrollment to 6-week follow-up |
| Effect of the Dietary Supplement on changes in waist circumference effect on cholesterol midway through the study | To evaluate the effect of the dietary supplement on changes in waist circumference compared baseline and placebo after 6 weeks of treatment. | From enrollment to 6-week follow-up |
| D009750 |
| Nutritional and Metabolic Diseases |